Xcelerate Inc.

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, FSNUY has a market cap of 126.9B. Regarding current trading prices, XCRT is priced at $0.02, while FSNUY trades at $14.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas FSNUY's P/E ratio is 23.87. In terms of profitability, XCRT's ROE is +0.90%, compared to FSNUY's ROE of +0.06%. Regarding short-term risk, XCRT is less volatile compared to FSNUY. This indicates potentially lower risk in terms of short-term price fluctuations for XCRT.Check FSNUY's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, FSNUF has a market cap of 31.7B. Regarding current trading prices, XCRT is priced at $0.02, while FSNUF trades at $56.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas FSNUF's P/E ratio is 23.98. In terms of profitability, XCRT's ROE is +0.90%, compared to FSNUF's ROE of +0.06%. Regarding short-term risk, XCRT is less volatile compared to FSNUF. This indicates potentially lower risk in terms of short-term price fluctuations for XCRT.Check FSNUF's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, JDHIF has a market cap of 26.5B. Regarding current trading prices, XCRT is priced at $0.02, while JDHIF trades at $8.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas JDHIF's P/E ratio is 39.50. In terms of profitability, XCRT's ROE is +0.90%, compared to JDHIF's ROE of +0.08%. Regarding short-term risk, XCRT is less volatile compared to JDHIF. This indicates potentially lower risk in terms of short-term price fluctuations for XCRT.Check JDHIF's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, JDHIY has a market cap of 21.8B. Regarding current trading prices, XCRT is priced at $0.02, while JDHIY trades at $6.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas JDHIY's P/E ratio is 32.48. In terms of profitability, XCRT's ROE is +0.90%, compared to JDHIY's ROE of +0.08%. Regarding short-term risk, XCRT is more volatile compared to JDHIY. This indicates potentially higher risk in terms of short-term price fluctuations for XCRT.Check JDHIY's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, FMCQF has a market cap of 15B. Regarding current trading prices, XCRT is priced at $0.02, while FMCQF trades at $51.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas FMCQF's P/E ratio is 19.62. In terms of profitability, XCRT's ROE is +0.90%, compared to FMCQF's ROE of +0.05%. Regarding short-term risk, XCRT is less volatile compared to FMCQF. This indicates potentially lower risk in terms of short-term price fluctuations for XCRT.Check FMCQF's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, BDUUY has a market cap of 12.8B. Regarding current trading prices, XCRT is priced at $0.02, while BDUUY trades at $32.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas BDUUY's P/E ratio is 28.36. In terms of profitability, XCRT's ROE is +0.90%, compared to BDUUY's ROE of +0.16%. Regarding short-term risk, XCRT is more volatile compared to BDUUY. This indicates potentially higher risk in terms of short-term price fluctuations for XCRT.Check BDUUY's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, IHHHF has a market cap of 10.5B. Regarding current trading prices, XCRT is priced at $0.02, while IHHHF trades at $1.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas IHHHF's P/E ratio is 17.00. In terms of profitability, XCRT's ROE is +0.90%, compared to IHHHF's ROE of +0.08%. Regarding short-term risk, XCRT is more volatile compared to IHHHF. This indicates potentially higher risk in terms of short-term price fluctuations for XCRT.Check IHHHF's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, BDULF has a market cap of 9.9B. Regarding current trading prices, XCRT is priced at $0.02, while BDULF trades at $0.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas BDULF's P/E ratio is 20.71. In terms of profitability, XCRT's ROE is +0.90%, compared to BDULF's ROE of +0.16%. Regarding short-term risk, XCRT is less volatile compared to BDULF. This indicates potentially lower risk in terms of short-term price fluctuations for XCRT.Check BDULF's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, BDUUF has a market cap of 9.4B. Regarding current trading prices, XCRT is priced at $0.02, while BDUUF trades at $0.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas BDUUF's P/E ratio is 19.67. In terms of profitability, XCRT's ROE is +0.90%, compared to BDUUF's ROE of +0.16%. Regarding short-term risk, XCRT is less volatile compared to BDUUF. This indicates potentially lower risk in terms of short-term price fluctuations for XCRT.Check BDUUF's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, WFHG has a market cap of 6.7B. Regarding current trading prices, XCRT is priced at $0.02, while WFHG trades at $105.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas WFHG's P/E ratio is N/A. In terms of profitability, XCRT's ROE is +0.90%, compared to WFHG's ROE of +0.28%. Regarding short-term risk, XCRT is less volatile compared to WFHG. This indicates potentially lower risk in terms of short-term price fluctuations for XCRT.Check WFHG's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, RMSYF has a market cap of 5.9B. Regarding current trading prices, XCRT is priced at $0.02, while RMSYF trades at $25.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas RMSYF's P/E ratio is 510.20. In terms of profitability, XCRT's ROE is +0.90%, compared to RMSYF's ROE of +0.01%. Regarding short-term risk, XCRT is less volatile compared to RMSYF. This indicates potentially lower risk in terms of short-term price fluctuations for XCRT.Check RMSYF's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, RMYHY has a market cap of 5.7B. Regarding current trading prices, XCRT is priced at $0.02, while RMYHY trades at $5.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas RMYHY's P/E ratio is 571.00. In terms of profitability, XCRT's ROE is +0.90%, compared to RMYHY's ROE of +0.01%. Regarding short-term risk, XCRT is more volatile compared to RMYHY. This indicates potentially higher risk in terms of short-term price fluctuations for XCRT.Check RMYHY's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, ANHGY has a market cap of 4B. Regarding current trading prices, XCRT is priced at $0.02, while ANHGY trades at $5.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas ANHGY's P/E ratio is 23.87. In terms of profitability, XCRT's ROE is +0.90%, compared to ANHGY's ROE of N/A. Regarding short-term risk, XCRT is more volatile compared to ANHGY. This indicates potentially higher risk in terms of short-term price fluctuations for XCRT.Check ANHGY's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, BUHPF has a market cap of 3.9B. Regarding current trading prices, XCRT is priced at $0.02, while BUHPF trades at $4.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas BUHPF's P/E ratio is 17.96. In terms of profitability, XCRT's ROE is +0.90%, compared to BUHPF's ROE of +0.27%. Regarding short-term risk, XCRT is less volatile compared to BUHPF. This indicates potentially lower risk in terms of short-term price fluctuations for XCRT.Check BUHPF's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, BUGDF has a market cap of 3.4B. Regarding current trading prices, XCRT is priced at $0.02, while BUGDF trades at $4.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas BUGDF's P/E ratio is 16.27. In terms of profitability, XCRT's ROE is +0.90%, compared to BUGDF's ROE of +0.27%. Regarding short-term risk, XCRT is less volatile compared to BUGDF. This indicates potentially lower risk in terms of short-term price fluctuations for XCRT.Check BUGDF's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, MCVEF has a market cap of 3B. Regarding current trading prices, XCRT is priced at $0.02, while MCVEF trades at $19.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas MCVEF's P/E ratio is 82.63. In terms of profitability, XCRT's ROE is +0.90%, compared to MCVEF's ROE of +0.09%. Regarding short-term risk, XCRT is less volatile compared to MCVEF. This indicates potentially lower risk in terms of short-term price fluctuations for XCRT.Check MCVEF's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, ORPEF has a market cap of 2.3B. Regarding current trading prices, XCRT is priced at $0.02, while ORPEF trades at $14.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas ORPEF's P/E ratio is 0.03. In terms of profitability, XCRT's ROE is +0.90%, compared to ORPEF's ROE of -0.23%. Regarding short-term risk, XCRT is less volatile compared to ORPEF. This indicates potentially lower risk in terms of short-term price fluctuations for XCRT.Check ORPEF's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, MCVEY has a market cap of 2.2B. Regarding current trading prices, XCRT is priced at $0.02, while MCVEY trades at $16.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas MCVEY's P/E ratio is 40.37. In terms of profitability, XCRT's ROE is +0.90%, compared to MCVEY's ROE of +0.09%. Regarding short-term risk, XCRT is less volatile compared to MCVEY. This indicates potentially lower risk in terms of short-term price fluctuations for XCRT.Check MCVEY's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, TTALF has a market cap of 1.6B. Regarding current trading prices, XCRT is priced at $0.02, while TTALF trades at $12.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas TTALF's P/E ratio is 19.33. In terms of profitability, XCRT's ROE is +0.90%, compared to TTALF's ROE of +0.16%. Regarding short-term risk, XCRT is more volatile compared to TTALF. This indicates potentially higher risk in terms of short-term price fluctuations for XCRT.Check TTALF's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, RAFLF has a market cap of 1.5B. Regarding current trading prices, XCRT is priced at $0.02, while RAFLF trades at $0.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas RAFLF's P/E ratio is 26.67. In terms of profitability, XCRT's ROE is +0.90%, compared to RAFLF's ROE of +0.03%. Regarding short-term risk, XCRT is less volatile compared to RAFLF. This indicates potentially lower risk in terms of short-term price fluctuations for XCRT.Check RAFLF's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, RHCGF has a market cap of 1.5B. Regarding current trading prices, XCRT is priced at $0.02, while RHCGF trades at $1.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas RHCGF's P/E ratio is -3.99. In terms of profitability, XCRT's ROE is +0.90%, compared to RHCGF's ROE of -0.07%. Regarding short-term risk, XCRT is less volatile compared to RHCGF. This indicates potentially lower risk in terms of short-term price fluctuations for XCRT.Check RHCGF's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, RYHTY has a market cap of 1.4B. Regarding current trading prices, XCRT is priced at $0.02, while RYHTY trades at $6.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas RYHTY's P/E ratio is -3.86. In terms of profitability, XCRT's ROE is +0.90%, compared to RYHTY's ROE of -0.02%. Regarding short-term risk, XCRT is more volatile compared to RYHTY. This indicates potentially higher risk in terms of short-term price fluctuations for XCRT.Check RYHTY's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, LWSCF has a market cap of 1.2B. Regarding current trading prices, XCRT is priced at $0.02, while LWSCF trades at $13.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas LWSCF's P/E ratio is 46.71. In terms of profitability, XCRT's ROE is +0.90%, compared to LWSCF's ROE of +0.06%. Regarding short-term risk, XCRT is more volatile compared to LWSCF. This indicates potentially higher risk in terms of short-term price fluctuations for XCRT.Check LWSCF's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, LTGHY has a market cap of 1.1B. Regarding current trading prices, XCRT is priced at $0.02, while LTGHY trades at $3.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas LTGHY's P/E ratio is -20.67. In terms of profitability, XCRT's ROE is +0.90%, compared to LTGHY's ROE of +0.40%. Regarding short-term risk, XCRT is less volatile compared to LTGHY. This indicates potentially lower risk in terms of short-term price fluctuations for XCRT.Check LTGHY's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, LTGHF has a market cap of 1.1B. Regarding current trading prices, XCRT is priced at $0.02, while LTGHF trades at $0.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas LTGHF's P/E ratio is -19.69. In terms of profitability, XCRT's ROE is +0.90%, compared to LTGHF's ROE of +0.40%. Regarding short-term risk, XCRT is less volatile compared to LTGHF. This indicates potentially lower risk in terms of short-term price fluctuations for XCRT.Check LTGHF's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, RHKJF has a market cap of 1B. Regarding current trading prices, XCRT is priced at $0.02, while RHKJF trades at $15.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas RHKJF's P/E ratio is 21.55. In terms of profitability, XCRT's ROE is +0.90%, compared to RHKJF's ROE of +0.03%. Regarding short-term risk, XCRT is less volatile compared to RHKJF. This indicates potentially lower risk in terms of short-term price fluctuations for XCRT.Check RHKJF's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, RKAGY has a market cap of 986.6M. Regarding current trading prices, XCRT is priced at $0.02, while RKAGY trades at $7.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas RKAGY's P/E ratio is 22.33. In terms of profitability, XCRT's ROE is +0.90%, compared to RKAGY's ROE of +0.03%. Regarding short-term risk, XCRT is more volatile compared to RKAGY. This indicates potentially higher risk in terms of short-term price fluctuations for XCRT.Check RKAGY's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, NWKHY has a market cap of 961.4M. Regarding current trading prices, XCRT is priced at $0.02, while NWKHY trades at $7.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas NWKHY's P/E ratio is 10.70. In terms of profitability, XCRT's ROE is +0.90%, compared to NWKHY's ROE of +0.13%. Regarding short-term risk, XCRT is more volatile compared to NWKHY. This indicates potentially higher risk in terms of short-term price fluctuations for XCRT.Check NWKHY's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, WHTCF has a market cap of 901.2M. Regarding current trading prices, XCRT is priced at $0.02, while WHTCF trades at $3.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas WHTCF's P/E ratio is -10.17. In terms of profitability, XCRT's ROE is +0.90%, compared to WHTCF's ROE of -0.15%. Regarding short-term risk, XCRT is more volatile compared to WHTCF. This indicates potentially higher risk in terms of short-term price fluctuations for XCRT.Check WHTCF's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, EXETF has a market cap of 805.5M. Regarding current trading prices, XCRT is priced at $0.02, while EXETF trades at $9.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas EXETF's P/E ratio is 13.73. In terms of profitability, XCRT's ROE is +0.90%, compared to EXETF's ROE of +0.65%. Regarding short-term risk, XCRT is more volatile compared to EXETF. This indicates potentially higher risk in terms of short-term price fluctuations for XCRT.Check EXETF's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, JXFGF has a market cap of 755.6M. Regarding current trading prices, XCRT is priced at $0.02, while JXFGF trades at $0.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas JXFGF's P/E ratio is 14.00. In terms of profitability, XCRT's ROE is +0.90%, compared to JXFGF's ROE of +0.03%. Regarding short-term risk, XCRT is less volatile compared to JXFGF. This indicates potentially lower risk in terms of short-term price fluctuations for XCRT.Check JXFGF's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, KDGTF has a market cap of 675.1M. Regarding current trading prices, XCRT is priced at $0.02, while KDGTF trades at $0.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas KDGTF's P/E ratio is -1.67. In terms of profitability, XCRT's ROE is +0.90%, compared to KDGTF's ROE of N/A. Regarding short-term risk, XCRT is more volatile compared to KDGTF. This indicates potentially higher risk in terms of short-term price fluctuations for XCRT.Check KDGTF's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, ORRRY has a market cap of 371.5M. Regarding current trading prices, XCRT is priced at $0.02, while ORRRY trades at $0.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas ORRRY's P/E ratio is -0.33. In terms of profitability, XCRT's ROE is +0.90%, compared to ORRRY's ROE of +7.04%. Regarding short-term risk, XCRT is more volatile compared to ORRRY. This indicates potentially higher risk in terms of short-term price fluctuations for XCRT.Check ORRRY's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, BTMDW has a market cap of 292.9M. Regarding current trading prices, XCRT is priced at $0.02, while BTMDW trades at $1.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas BTMDW's P/E ratio is 0.05. In terms of profitability, XCRT's ROE is +0.90%, compared to BTMDW's ROE of -0.31%. Regarding short-term risk, XCRT is less volatile compared to BTMDW. This indicates potentially lower risk in terms of short-term price fluctuations for XCRT.Check BTMDW's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, EVGRF has a market cap of 236M. Regarding current trading prices, XCRT is priced at $0.02, while EVGRF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas EVGRF's P/E ratio is N/A. In terms of profitability, XCRT's ROE is +0.90%, compared to EVGRF's ROE of +0.21%. Regarding short-term risk, XCRT is less volatile compared to EVGRF. This indicates potentially lower risk in terms of short-term price fluctuations for XCRT.Check EVGRF's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, MKLNF has a market cap of 217.6M. Regarding current trading prices, XCRT is priced at $0.02, while MKLNF trades at $11.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas MKLNF's P/E ratio is 19.23. In terms of profitability, XCRT's ROE is +0.90%, compared to MKLNF's ROE of +0.14%. Regarding short-term risk, XCRT is more volatile compared to MKLNF. This indicates potentially higher risk in terms of short-term price fluctuations for XCRT.Check MKLNF's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, MFCSF has a market cap of 198.6M. Regarding current trading prices, XCRT is priced at $0.02, while MFCSF trades at $10.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas MFCSF's P/E ratio is 5.66. In terms of profitability, XCRT's ROE is +0.90%, compared to MFCSF's ROE of +0.90%. Regarding short-term risk, XCRT is more volatile compared to MFCSF. This indicates potentially higher risk in terms of short-term price fluctuations for XCRT.Check MFCSF's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, CHHHF has a market cap of 135M. Regarding current trading prices, XCRT is priced at $0.02, while CHHHF trades at $2.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas CHHHF's P/E ratio is -107.00. In terms of profitability, XCRT's ROE is +0.90%, compared to CHHHF's ROE of -0.02%. Regarding short-term risk, XCRT is more volatile compared to CHHHF. This indicates potentially higher risk in terms of short-term price fluctuations for XCRT.Check CHHHF's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, COLRF has a market cap of 123M. Regarding current trading prices, XCRT is priced at $0.02, while COLRF trades at $0.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas COLRF's P/E ratio is -8.00. In terms of profitability, XCRT's ROE is +0.90%, compared to COLRF's ROE of +0.01%. Regarding short-term risk, XCRT is less volatile compared to COLRF. This indicates potentially lower risk in terms of short-term price fluctuations for XCRT.Check COLRF's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, VTIAF has a market cap of 95.9M. Regarding current trading prices, XCRT is priced at $0.02, while VTIAF trades at $5.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas VTIAF's P/E ratio is -6.87. In terms of profitability, XCRT's ROE is +0.90%, compared to VTIAF's ROE of -0.63%. Regarding short-term risk, XCRT is less volatile compared to VTIAF. This indicates potentially lower risk in terms of short-term price fluctuations for XCRT.Check VTIAF's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, MCIOF has a market cap of 54M. Regarding current trading prices, XCRT is priced at $0.02, while MCIOF trades at $0.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas MCIOF's P/E ratio is -1.22. In terms of profitability, XCRT's ROE is +0.90%, compared to MCIOF's ROE of N/A. Regarding short-term risk, XCRT is more volatile compared to MCIOF. This indicates potentially higher risk in terms of short-term price fluctuations for XCRT.Check MCIOF's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, ASSF has a market cap of 45.3M. Regarding current trading prices, XCRT is priced at $0.02, while ASSF trades at $1.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas ASSF's P/E ratio is -33.33. In terms of profitability, XCRT's ROE is +0.90%, compared to ASSF's ROE of -6.63%. Regarding short-term risk, XCRT is more volatile compared to ASSF. This indicates potentially higher risk in terms of short-term price fluctuations for XCRT.Check ASSF's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, KONEF has a market cap of 44.3M. Regarding current trading prices, XCRT is priced at $0.02, while KONEF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas KONEF's P/E ratio is N/A. In terms of profitability, XCRT's ROE is +0.90%, compared to KONEF's ROE of -6.56%. Regarding short-term risk, XCRT is less volatile compared to KONEF. This indicates potentially lower risk in terms of short-term price fluctuations for XCRT.Check KONEF's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, USNU has a market cap of 22.2M. Regarding current trading prices, XCRT is priced at $0.02, while USNU trades at $1.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas USNU's P/E ratio is -9.41. In terms of profitability, XCRT's ROE is +0.90%, compared to USNU's ROE of -0.55%. Regarding short-term risk, XCRT is less volatile compared to USNU. This indicates potentially lower risk in terms of short-term price fluctuations for XCRT.Check USNU's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, NVLPF has a market cap of 20.8M. Regarding current trading prices, XCRT is priced at $0.02, while NVLPF trades at $0.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas NVLPF's P/E ratio is 23.82. In terms of profitability, XCRT's ROE is +0.90%, compared to NVLPF's ROE of +0.01%. Regarding short-term risk, XCRT is more volatile compared to NVLPF. This indicates potentially higher risk in terms of short-term price fluctuations for XCRT.Check NVLPF's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, HQDA has a market cap of 18.6M. Regarding current trading prices, XCRT is priced at $0.02, while HQDA trades at $0.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas HQDA's P/E ratio is N/A. In terms of profitability, XCRT's ROE is +0.90%, compared to HQDA's ROE of +0.00%. Regarding short-term risk, XCRT is more volatile compared to HQDA. This indicates potentially higher risk in terms of short-term price fluctuations for XCRT.Check HQDA's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, FPCG has a market cap of 10.1M. Regarding current trading prices, XCRT is priced at $0.02, while FPCG trades at $1,025.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas FPCG's P/E ratio is 0.09. In terms of profitability, XCRT's ROE is +0.90%, compared to FPCG's ROE of +0.00%. Regarding short-term risk, XCRT is more volatile compared to FPCG. This indicates potentially higher risk in terms of short-term price fluctuations for XCRT.Check FPCG's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, NUMIF has a market cap of 9.9M. Regarding current trading prices, XCRT is priced at $0.02, while NUMIF trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas NUMIF's P/E ratio is -1.03. In terms of profitability, XCRT's ROE is +0.90%, compared to NUMIF's ROE of -2.96%. Regarding short-term risk, XCRT is less volatile compared to NUMIF. This indicates potentially lower risk in terms of short-term price fluctuations for XCRT.Check NUMIF's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, HLYK has a market cap of 7.9M. Regarding current trading prices, XCRT is priced at $0.02, while HLYK trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas HLYK's P/E ratio is -1.39. In terms of profitability, XCRT's ROE is +0.90%, compared to HLYK's ROE of +1.42%. Regarding short-term risk, XCRT is less volatile compared to HLYK. This indicates potentially lower risk in terms of short-term price fluctuations for XCRT.Check HLYK's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, GBCS has a market cap of 7.7M. Regarding current trading prices, XCRT is priced at $0.02, while GBCS trades at $2.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas GBCS's P/E ratio is -2.40. In terms of profitability, XCRT's ROE is +0.90%, compared to GBCS's ROE of +0.55%. Regarding short-term risk, XCRT is less volatile compared to GBCS. This indicates potentially lower risk in terms of short-term price fluctuations for XCRT.Check GBCS's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, BICX has a market cap of 6.3M. Regarding current trading prices, XCRT is priced at $0.02, while BICX trades at $0.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas BICX's P/E ratio is -1.00. In terms of profitability, XCRT's ROE is +0.90%, compared to BICX's ROE of +0.39%. Regarding short-term risk, XCRT is more volatile compared to BICX. This indicates potentially higher risk in terms of short-term price fluctuations for XCRT.Check BICX's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, VLXC has a market cap of 5.7M. Regarding current trading prices, XCRT is priced at $0.02, while VLXC trades at $0.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas VLXC's P/E ratio is -8.00. In terms of profitability, XCRT's ROE is +0.90%, compared to VLXC's ROE of +0.58%. Regarding short-term risk, XCRT is less volatile compared to VLXC. This indicates potentially lower risk in terms of short-term price fluctuations for XCRT.Check VLXC's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, RVLWF has a market cap of 5.3M. Regarding current trading prices, XCRT is priced at $0.02, while RVLWF trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas RVLWF's P/E ratio is -0.30. In terms of profitability, XCRT's ROE is +0.90%, compared to RVLWF's ROE of +3.95%. Regarding short-term risk, XCRT is more volatile compared to RVLWF. This indicates potentially higher risk in terms of short-term price fluctuations for XCRT.Check RVLWF's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, RHEP has a market cap of 3.9M. Regarding current trading prices, XCRT is priced at $0.02, while RHEP trades at $1.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas RHEP's P/E ratio is -0.76. In terms of profitability, XCRT's ROE is +0.90%, compared to RHEP's ROE of +1.14%. Regarding short-term risk, XCRT is less volatile compared to RHEP. This indicates potentially lower risk in terms of short-term price fluctuations for XCRT.Check RHEP's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, EPWCF has a market cap of 2.5M. Regarding current trading prices, XCRT is priced at $0.02, while EPWCF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas EPWCF's P/E ratio is -0.00. In terms of profitability, XCRT's ROE is +0.90%, compared to EPWCF's ROE of +0.00%. Regarding short-term risk, XCRT is less volatile compared to EPWCF. This indicates potentially lower risk in terms of short-term price fluctuations for XCRT.Check EPWCF's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, GRST has a market cap of 2.3M. Regarding current trading prices, XCRT is priced at $0.02, while GRST trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas GRST's P/E ratio is N/A. In terms of profitability, XCRT's ROE is +0.90%, compared to GRST's ROE of +0.28%. Regarding short-term risk, XCRT is more volatile compared to GRST. This indicates potentially higher risk in terms of short-term price fluctuations for XCRT.Check GRST's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, TOKIF has a market cap of 1.8M. Regarding current trading prices, XCRT is priced at $0.02, while TOKIF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas TOKIF's P/E ratio is -0.01. In terms of profitability, XCRT's ROE is +0.90%, compared to TOKIF's ROE of -0.83%. Regarding short-term risk, XCRT is less volatile compared to TOKIF. This indicates potentially lower risk in terms of short-term price fluctuations for XCRT.Check TOKIF's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, SMAS has a market cap of 1.5M. Regarding current trading prices, XCRT is priced at $0.02, while SMAS trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas SMAS's P/E ratio is N/A. In terms of profitability, XCRT's ROE is +0.90%, compared to SMAS's ROE of N/A. Regarding short-term risk, XCRT is less volatile compared to SMAS. This indicates potentially lower risk in terms of short-term price fluctuations for XCRT.Check SMAS's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, MDGP has a market cap of 1.5M. Regarding current trading prices, XCRT is priced at $0.02, while MDGP trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas MDGP's P/E ratio is N/A. In terms of profitability, XCRT's ROE is +0.90%, compared to MDGP's ROE of -2.19%. Regarding short-term risk, XCRT is more volatile compared to MDGP. This indicates potentially higher risk in terms of short-term price fluctuations for XCRT.Check MDGP's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, NOVC has a market cap of 1.2M. Regarding current trading prices, XCRT is priced at $0.02, while NOVC trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas NOVC's P/E ratio is -0.20. In terms of profitability, XCRT's ROE is +0.90%, compared to NOVC's ROE of +0.12%. Regarding short-term risk, XCRT is more volatile compared to NOVC. This indicates potentially higher risk in terms of short-term price fluctuations for XCRT.Check NOVC's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, PHMB has a market cap of 1.1M. Regarding current trading prices, XCRT is priced at $0.02, while PHMB trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas PHMB's P/E ratio is N/A. In terms of profitability, XCRT's ROE is +0.90%, compared to PHMB's ROE of N/A. Regarding short-term risk, XCRT is less volatile compared to PHMB. This indicates potentially lower risk in terms of short-term price fluctuations for XCRT.Check PHMB's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, JNHMF has a market cap of 870.6K. Regarding current trading prices, XCRT is priced at $0.02, while JNHMF trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas JNHMF's P/E ratio is -0.17. In terms of profitability, XCRT's ROE is +0.90%, compared to JNHMF's ROE of +0.47%. Regarding short-term risk, XCRT is less volatile compared to JNHMF. This indicates potentially lower risk in terms of short-term price fluctuations for XCRT.Check JNHMF's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, GNOW has a market cap of 859.7K. Regarding current trading prices, XCRT is priced at $0.02, while GNOW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas GNOW's P/E ratio is -0.01. In terms of profitability, XCRT's ROE is +0.90%, compared to GNOW's ROE of +0.00%. Regarding short-term risk, XCRT is more volatile compared to GNOW. This indicates potentially higher risk in terms of short-term price fluctuations for XCRT.Check GNOW's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, ERUC has a market cap of 638.1K. Regarding current trading prices, XCRT is priced at $0.02, while ERUC trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas ERUC's P/E ratio is N/A. In terms of profitability, XCRT's ROE is +0.90%, compared to ERUC's ROE of N/A. Regarding short-term risk, XCRT is more volatile compared to ERUC. This indicates potentially higher risk in terms of short-term price fluctuations for XCRT.Check ERUC's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, JRSS has a market cap of 507.6K. Regarding current trading prices, XCRT is priced at $0.02, while JRSS trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas JRSS's P/E ratio is -0.06. In terms of profitability, XCRT's ROE is +0.90%, compared to JRSS's ROE of +1.88%. Regarding short-term risk, XCRT is less volatile compared to JRSS. This indicates potentially lower risk in terms of short-term price fluctuations for XCRT.Check JRSS's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, DPAT has a market cap of 481.6K. Regarding current trading prices, XCRT is priced at $0.02, while DPAT trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas DPAT's P/E ratio is -2.00. In terms of profitability, XCRT's ROE is +0.90%, compared to DPAT's ROE of +0.45%. Regarding short-term risk, XCRT is more volatile compared to DPAT. This indicates potentially higher risk in terms of short-term price fluctuations for XCRT.Check DPAT's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, MSITF has a market cap of 480K. Regarding current trading prices, XCRT is priced at $0.02, while MSITF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas MSITF's P/E ratio is -0.10. In terms of profitability, XCRT's ROE is +0.90%, compared to MSITF's ROE of N/A. Regarding short-term risk, XCRT is less volatile compared to MSITF. This indicates potentially lower risk in terms of short-term price fluctuations for XCRT.Check MSITF's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, FCHS has a market cap of 395.5K. Regarding current trading prices, XCRT is priced at $0.02, while FCHS trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas FCHS's P/E ratio is -0.13. In terms of profitability, XCRT's ROE is +0.90%, compared to FCHS's ROE of +0.08%. Regarding short-term risk, XCRT is less volatile compared to FCHS. This indicates potentially lower risk in terms of short-term price fluctuations for XCRT.Check FCHS's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, KJFI has a market cap of 374.6K. Regarding current trading prices, XCRT is priced at $0.02, while KJFI trades at $0.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas KJFI's P/E ratio is -0.06. In terms of profitability, XCRT's ROE is +0.90%, compared to KJFI's ROE of +0.00%. Regarding short-term risk, XCRT is less volatile compared to KJFI. This indicates potentially lower risk in terms of short-term price fluctuations for XCRT.Check KJFI's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, ARPC has a market cap of 336.6K. Regarding current trading prices, XCRT is priced at $0.02, while ARPC trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas ARPC's P/E ratio is N/A. In terms of profitability, XCRT's ROE is +0.90%, compared to ARPC's ROE of +3.10%. Regarding short-term risk, XCRT is less volatile compared to ARPC. This indicates potentially lower risk in terms of short-term price fluctuations for XCRT.Check ARPC's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, NXGT has a market cap of 332.9K. Regarding current trading prices, XCRT is priced at $0.02, while NXGT trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas NXGT's P/E ratio is N/A. In terms of profitability, XCRT's ROE is +0.90%, compared to NXGT's ROE of +0.06%. Regarding short-term risk, XCRT is less volatile compared to NXGT. This indicates potentially lower risk in terms of short-term price fluctuations for XCRT.Check NXGT's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, BNYN has a market cap of 286K. Regarding current trading prices, XCRT is priced at $0.02, while BNYN trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas BNYN's P/E ratio is N/A. In terms of profitability, XCRT's ROE is +0.90%, compared to BNYN's ROE of -14.10%. Regarding short-term risk, XCRT is less volatile compared to BNYN. This indicates potentially lower risk in terms of short-term price fluctuations for XCRT.Check BNYN's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, DRWN has a market cap of 239.8K. Regarding current trading prices, XCRT is priced at $0.02, while DRWN trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas DRWN's P/E ratio is N/A. In terms of profitability, XCRT's ROE is +0.90%, compared to DRWN's ROE of -0.01%. Regarding short-term risk, XCRT is less volatile compared to DRWN. This indicates potentially lower risk in terms of short-term price fluctuations for XCRT.Check DRWN's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, SETO has a market cap of 160.9K. Regarding current trading prices, XCRT is priced at $0.02, while SETO trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas SETO's P/E ratio is -1.29. In terms of profitability, XCRT's ROE is +0.90%, compared to SETO's ROE of +0.00%. Regarding short-term risk, XCRT is more volatile compared to SETO. This indicates potentially higher risk in terms of short-term price fluctuations for XCRT.Check SETO's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, TPIA has a market cap of 113.8K. Regarding current trading prices, XCRT is priced at $0.02, while TPIA trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas TPIA's P/E ratio is -0.15. In terms of profitability, XCRT's ROE is +0.90%, compared to TPIA's ROE of +0.60%. Regarding short-term risk, XCRT is less volatile compared to TPIA. This indicates potentially lower risk in terms of short-term price fluctuations for XCRT.Check TPIA's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, AMBD has a market cap of 85.6K. Regarding current trading prices, XCRT is priced at $0.02, while AMBD trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas AMBD's P/E ratio is N/A. In terms of profitability, XCRT's ROE is +0.90%, compared to AMBD's ROE of +1.11%. Regarding short-term risk, XCRT is less volatile compared to AMBD. This indicates potentially lower risk in terms of short-term price fluctuations for XCRT.Check AMBD's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, NMHLY has a market cap of 41.7K. Regarding current trading prices, XCRT is priced at $0.02, while NMHLY trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas NMHLY's P/E ratio is 0.02. In terms of profitability, XCRT's ROE is +0.90%, compared to NMHLY's ROE of N/A. Regarding short-term risk, XCRT is more volatile compared to NMHLY. This indicates potentially higher risk in terms of short-term price fluctuations for XCRT.Check NMHLY's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, CLRD has a market cap of 32.5K. Regarding current trading prices, XCRT is priced at $0.02, while CLRD trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas CLRD's P/E ratio is N/A. In terms of profitability, XCRT's ROE is +0.90%, compared to CLRD's ROE of +0.38%. Regarding short-term risk, XCRT is less volatile compared to CLRD. This indicates potentially lower risk in terms of short-term price fluctuations for XCRT.Check CLRD's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, HSMD has a market cap of 19.2K. Regarding current trading prices, XCRT is priced at $0.02, while HSMD trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas HSMD's P/E ratio is -0.01. In terms of profitability, XCRT's ROE is +0.90%, compared to HSMD's ROE of -0.04%. Regarding short-term risk, XCRT is more volatile compared to HSMD. This indicates potentially higher risk in terms of short-term price fluctuations for XCRT.Check HSMD's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, SCAL has a market cap of 17.4K. Regarding current trading prices, XCRT is priced at $0.02, while SCAL trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas SCAL's P/E ratio is 0.04. In terms of profitability, XCRT's ROE is +0.90%, compared to SCAL's ROE of +0.07%. Regarding short-term risk, XCRT is more volatile compared to SCAL. This indicates potentially higher risk in terms of short-term price fluctuations for XCRT.Check SCAL's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, CEVE has a market cap of 15.4K. Regarding current trading prices, XCRT is priced at $0.02, while CEVE trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas CEVE's P/E ratio is N/A. In terms of profitability, XCRT's ROE is +0.90%, compared to CEVE's ROE of +2.26%. Regarding short-term risk, XCRT is more volatile compared to CEVE. This indicates potentially higher risk in terms of short-term price fluctuations for XCRT.Check CEVE's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, GENN has a market cap of 12.1K. Regarding current trading prices, XCRT is priced at $0.02, while GENN trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas GENN's P/E ratio is -0.01. In terms of profitability, XCRT's ROE is +0.90%, compared to GENN's ROE of +0.00%. Regarding short-term risk, XCRT is less volatile compared to GENN. This indicates potentially lower risk in terms of short-term price fluctuations for XCRT.Check GENN's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, CHCR has a market cap of 12K. Regarding current trading prices, XCRT is priced at $0.02, while CHCR trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas CHCR's P/E ratio is -0.00. In terms of profitability, XCRT's ROE is +0.90%, compared to CHCR's ROE of N/A. Regarding short-term risk, XCRT is more volatile compared to CHCR. This indicates potentially higher risk in terms of short-term price fluctuations for XCRT.Check CHCR's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, ACGI has a market cap of 10.5K. Regarding current trading prices, XCRT is priced at $0.02, while ACGI trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas ACGI's P/E ratio is N/A. In terms of profitability, XCRT's ROE is +0.90%, compared to ACGI's ROE of +1.11%. Regarding short-term risk, XCRT is less volatile compared to ACGI. This indicates potentially lower risk in terms of short-term price fluctuations for XCRT.Check ACGI's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, NRTSF has a market cap of 7.8K. Regarding current trading prices, XCRT is priced at $0.02, while NRTSF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas NRTSF's P/E ratio is 0.01. In terms of profitability, XCRT's ROE is +0.90%, compared to NRTSF's ROE of +0.00%. Regarding short-term risk, XCRT is less volatile compared to NRTSF. This indicates potentially lower risk in terms of short-term price fluctuations for XCRT.Check NRTSF's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, NAFS has a market cap of 7K. Regarding current trading prices, XCRT is priced at $0.02, while NAFS trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas NAFS's P/E ratio is N/A. In terms of profitability, XCRT's ROE is +0.90%, compared to NAFS's ROE of +1.02%. Regarding short-term risk, XCRT is more volatile compared to NAFS. This indicates potentially higher risk in terms of short-term price fluctuations for XCRT.Check NAFS's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, PRMD has a market cap of 5.6K. Regarding current trading prices, XCRT is priced at $0.02, while PRMD trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas PRMD's P/E ratio is N/A. In terms of profitability, XCRT's ROE is +0.90%, compared to PRMD's ROE of +0.73%. Regarding short-term risk, XCRT is less volatile compared to PRMD. This indicates potentially lower risk in terms of short-term price fluctuations for XCRT.Check PRMD's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, MSGP has a market cap of 5.2K. Regarding current trading prices, XCRT is priced at $0.02, while MSGP trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas MSGP's P/E ratio is N/A. In terms of profitability, XCRT's ROE is +0.90%, compared to MSGP's ROE of +0.27%. Regarding short-term risk, XCRT is more volatile compared to MSGP. This indicates potentially higher risk in terms of short-term price fluctuations for XCRT.Check MSGP's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, SLHPF has a market cap of 3.9K. Regarding current trading prices, XCRT is priced at $0.02, while SLHPF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas SLHPF's P/E ratio is N/A. In terms of profitability, XCRT's ROE is +0.90%, compared to SLHPF's ROE of +0.00%. Regarding short-term risk, XCRT is less volatile compared to SLHPF. This indicates potentially lower risk in terms of short-term price fluctuations for XCRT.Check SLHPF's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, WEQL has a market cap of 3.5K. Regarding current trading prices, XCRT is priced at $0.02, while WEQL trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas WEQL's P/E ratio is N/A. In terms of profitability, XCRT's ROE is +0.90%, compared to WEQL's ROE of +0.21%. Regarding short-term risk, XCRT is more volatile compared to WEQL. This indicates potentially higher risk in terms of short-term price fluctuations for XCRT.Check WEQL's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, BBAL has a market cap of 3.4K. Regarding current trading prices, XCRT is priced at $0.02, while BBAL trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas BBAL's P/E ratio is N/A. In terms of profitability, XCRT's ROE is +0.90%, compared to BBAL's ROE of +0.45%. Regarding short-term risk, XCRT is more volatile compared to BBAL. This indicates potentially higher risk in terms of short-term price fluctuations for XCRT.Check BBAL's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, PAOG has a market cap of 2.5K. Regarding current trading prices, XCRT is priced at $0.02, while PAOG trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas PAOG's P/E ratio is N/A. In terms of profitability, XCRT's ROE is +0.90%, compared to PAOG's ROE of +0.05%. Regarding short-term risk, XCRT is less volatile compared to PAOG. This indicates potentially lower risk in terms of short-term price fluctuations for XCRT.Check PAOG's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, NMMCF has a market cap of 2.1K. Regarding current trading prices, XCRT is priced at $0.02, while NMMCF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas NMMCF's P/E ratio is 0.00. In terms of profitability, XCRT's ROE is +0.90%, compared to NMMCF's ROE of +0.00%. Regarding short-term risk, XCRT is less volatile compared to NMMCF. This indicates potentially lower risk in terms of short-term price fluctuations for XCRT.Check NMMCF's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, PPRG has a market cap of 1.6K. Regarding current trading prices, XCRT is priced at $0.02, while PPRG trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas PPRG's P/E ratio is N/A. In terms of profitability, XCRT's ROE is +0.90%, compared to PPRG's ROE of -0.58%. Regarding short-term risk, XCRT is more volatile compared to PPRG. This indicates potentially higher risk in terms of short-term price fluctuations for XCRT.Check PPRG's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, OHAQ has a market cap of 1.4K. Regarding current trading prices, XCRT is priced at $0.02, while OHAQ trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas OHAQ's P/E ratio is 0.01. In terms of profitability, XCRT's ROE is +0.90%, compared to OHAQ's ROE of +0.09%. Regarding short-term risk, XCRT is more volatile compared to OHAQ. This indicates potentially higher risk in terms of short-term price fluctuations for XCRT.Check OHAQ's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, BNKL has a market cap of 1.2K. Regarding current trading prices, XCRT is priced at $0.02, while BNKL trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas BNKL's P/E ratio is N/A. In terms of profitability, XCRT's ROE is +0.90%, compared to BNKL's ROE of -7.69%. Regarding short-term risk, XCRT is more volatile compared to BNKL. This indicates potentially higher risk in terms of short-term price fluctuations for XCRT.Check BNKL's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, MAHN has a market cap of 1.2K. Regarding current trading prices, XCRT is priced at $0.02, while MAHN trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas MAHN's P/E ratio is 0.05. In terms of profitability, XCRT's ROE is +0.90%, compared to MAHN's ROE of N/A. Regarding short-term risk, XCRT is less volatile compared to MAHN. This indicates potentially lower risk in terms of short-term price fluctuations for XCRT.Check MAHN's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, SLHGF has a market cap of 398. Regarding current trading prices, XCRT is priced at $0.02, while SLHGF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas SLHGF's P/E ratio is N/A. In terms of profitability, XCRT's ROE is +0.90%, compared to SLHGF's ROE of +0.00%. Regarding short-term risk, XCRT is more volatile compared to SLHGF. This indicates potentially higher risk in terms of short-term price fluctuations for XCRT.Check SLHGF's competition here

XCRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XCRT stands at 6.8M. In comparison, NMSCA has a market cap of 275. Regarding current trading prices, XCRT is priced at $0.02, while NMSCA trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XCRT currently has a P/E ratio of N/A, whereas NMSCA's P/E ratio is N/A. In terms of profitability, XCRT's ROE is +0.90%, compared to NMSCA's ROE of +0.02%. Regarding short-term risk, XCRT is more volatile compared to NMSCA. This indicates potentially higher risk in terms of short-term price fluctuations for XCRT.Check NMSCA's competition here